Shigella vaccine

The Shigella vaccine developed by Vaxine Pty Ltd is an investigational vaccine candidate designed to prevent shigellosis, a severe form of bacterial dysentery caused by *Shigella* species. The vaccine is built upon Vaxine's proprietary Advax adjuvant platform, which utilizes delta-inulin to enhance both humoral and cellular immune responses. While specific antigen details are often proprietary in early development, the candidate typically employs recombinant proteins to elicit broad protection against multiple *Shigella* serotypes. By leveraging the Advax technology, the vaccine aims to provide a potent and safe immunogenic profile, addressing a significant global health need, particularly for children in low-resource settings and travelers.

Other names

Shigella vaccine (Vaxine Pty Ltd)Advax-Shigella vaccine